Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Omnicell ( (OMCL) ).
On September 30, 2025, Omnicell, Inc.’s board of directors adopted the fourth amended and restated bylaws, effective immediately. These amendments enhance procedural mechanics and disclosure requirements for stockholder nominations and proposals, address matters related to Rule 14a-19 under the Exchange Act, clarify personal jurisdiction provisions, and make various updates, impacting the company’s governance and stakeholder engagement.
The most recent analyst rating on (OMCL) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Omnicell stock, see the OMCL Stock Forecast page.
Spark’s Take on OMCL Stock
According to Spark, TipRanks’ AI Analyst, OMCL is a Neutral.
Omnicell’s overall stock score is driven by a positive earnings call that highlights revenue growth and strategic initiatives. However, high valuation metrics and technical indicators suggest caution. Financial performance is stable but not exceptional, with challenges in revenue growth and operational efficiency. The absence of corporate events and a dividend yield further tempers the score.
To see Spark’s full report on OMCL stock, click here.
More about Omnicell
Omnicell, Inc. operates in the healthcare industry, providing medication management solutions and adherence tools for healthcare systems and pharmacies.
Average Trading Volume: 527,023
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.42B
See more data about OMCL stock on TipRanks’ Stock Analysis page.